Therapeutics Metabolic and Endocrine Agents

Medical management of metabolic dysfunction in PCOS

Duleba AJ

Published March 2012 Steroids, 77(4), 306-311
DOI 10.1016/j.steroids.2011.11.014 PMC PMC3409585

RRM Academy Synopsis

PCOS metabolic drugs have limited evidence of long-term benefit

A 2012 one-author review of seven drugs finds very limited evidence of real long-term benefit in PCOS (polycystic ovary syndrome, now PMOS). Recent trials of metformin against placebo found no significant metabolic benefit.

Key Findings

  • In a large randomized trial of people with prediabetes, a different group from PCOS, metformin cut diabetes cases by 31% over 2.8 years on average. Intensive lifestyle change cut them by 58%.
  • In PCOS, a recent meta-analysis found no significant metformin effect on fasting insulin, waist circumference, HDL cholesterol, total cholesterol or triglycerides.
  • Thiazolidinediones improved insulin sensitivity in multiple studies, including placebo-controlled trials, but most trials found no significant improvement in dyslipidemia, and weight gain was often reported.
  • Statins consistently improved the lipid profile and markers of systemic inflammation, with variable effects on insulin sensitivity. Statins are listed as pregnancy category X.
  • Acarbose, naltrexone, orlistat and vitamin D each had few PCOS studies, and the review found no placebo-controlled or randomized trials of vitamin D.

Interpretation

This 2012 narrative review describes seven drug classes used for metabolic treatment in PCOS, one at a time. Statins and thiazolidinediones show the clearest metabolic effects, while metformin's benefit in PCOS looks smaller than its benefit in prediabetes. The author notes that no long-term risk-to-benefit data exist for any of these drugs. The findings support larger, longer-term studies of these treatments in PCOS/PMOS.

RRM Context

In 2026 an international consensus renamed PCOS as PMOS, a name that reflects its metabolic features. Restorative reproductive medicine treats those features as root-cause questions about each woman. The review calls for finding likely responders to each therapy, which fits individual care.

Abstract

Polycystic ovary syndrome (PCOS) is associated with metabolic derangements including insulin resistance, dyslipidemia, systemic inflammation and endothelial dysfunction. There is a growing need to develop pharmacologic interventions to improve metabolic function in women with PCOS. Medications that have been tested in patients with PCOS include metformin, thiazolidinediones, acarbose, naltrexone, orlistat, vitamin D and statins. Metformin decreases hepatic gluconeogenesis and free fatty acid oxidation while increasing peripheral glucose uptake. Early studies in PCOS suggested that metformin indirectly reduces insulin level, dyslipidemia and systemic inflammation; however, recent placebo-controlled trials failed to demonstrate significant metabolic benefit. Thiazolidinediones act primarily by increasing peripheral glucose uptake. Most studies in PCOS have demonstrated that thiazolidinediones reduce insulin resistance; however, effects on dyslipidemia were disappointing. Use of thiazolidinediones is associated with weight gain and major complications. Acarbose reduces digestion of polysaccharides. Studies in PCOS yielded inconsistent effects of acarbose on insulin sensitivity and no significant improvement of dyslipidemia. Naltrexone reduces appetite and modulates insulin release; its use in PCOS may reduce hyperinsulinemia. Orlistat decreases absorption of dietary fats; studies in PCOS suggest beneficial effects on insulin sensitivity. Vitamin D may improve insulin sensitivity but mixed results on lipid profile in PCOS have been reported. Statins are competitive inhibitors of the key enzyme regulating the mevalonate pathway; their effects are related to reduced cholesterol production as well as anti-inflammatory and anti-oxidant properties. In women with PCOS, statins reduce hyperandrogenism, improve lipid profile and reduce systemic inflammation while the effects on insulin sensitivity are variable. Use of statins is contraindicated in pregnancy.

Topics

By this author

Related research

Therapeutics › Metabolic and Endocrine Agents › Insulin Sensitizing Agents
Antoni J. Duleba
A Duleba
DOI 10.1016/j.steroids.2011.11.014 10.1016/j.steroids.2011.11.014 Duleba et al. 2012, Duleba 2012